Shield Therapeutics plc (LON:STX – Get Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 8.99 and traded as low as GBX 6.34. Shield Therapeutics shares last traded at GBX 6.50, with a volume of 981,211 shares traded.
Shield Therapeutics Trading Up 1.6%
The firm’s 50-day simple moving average is GBX 7.25 and its 200-day simple moving average is GBX 8.99. The firm has a market capitalization of £69.52 million, a P/E ratio of -3.25 and a beta of 1.78. The company has a quick ratio of 2.16, a current ratio of 0.90 and a debt-to-equity ratio of -199.87.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
